The secretome signature for identifying biomarkers in COVID-19 severe forms

Archive ouverte

Blangy-Letheule, Angélique | Bourgoin-Voillard, Sandrine | Habert, Damien | Persello, Antoine | Dhot, Justine | Seve, Michel | Roquilly, Antoine | Rozec, Bertrand | Dewaard, Michel | Courty, José | Lauzier, Benjamin

Edité par CCSD -

International audience. To face the COVID-19 pandemic caused by SARS-CoV-2 infection that continues spreading worldwide andlead more than 4 million of deaths, many efforts are still being employed to better understand themolecular pathology of the different levels of COVID-19 severity and develop biomarker strategies enablingits early diagnosis. Knowing that the plasma secretome reflects the functional state of cells underpathological evolution, we used a label free mass spectrometry method to define a protein plasmasecretome signature of COVID-19 severe forms leading to intensive care unit (ICU) hospitalization andcompare the secretome signature to severe pneumonia not from COVID patients also leading to ICUhospitalization. This intrigued us to reveal specific SARS-CoV-2 infection effects on plasma content. For thispurpose, the proteome plasma profile of 33 patients hospitalized from severe pneumonia after a SARS-CoV-2 infection, 126 patients hospitalized from severe pneumonia without prior to SARS-CoV-2 infection and 20control patients were analyzed. The proteome profile was obtained after an enrichment of the lowabundant proteins (Proteominer® technology), a trypsin/Lys C digestion and a mass spectrometry analysisby using a NanoAcquity C18 and SYNAPT G2Si mass spectrometer system (Waters) operating in a highdefinition LC-MSE mode. Based on the quantification of 302 proteins (FDR 1%), we identified 57 significantlyderegulated proteins (DEP) in patients hospitalized after a SARS-CoV-2 infection. Several of those DEP areinvolved in complement activation, platelet degranulation that are known to contribute to the pathogenesisand other biological processes that are less known to contribute to the pathogenesis, such as lipoproteinsynthesis. Our approach contributes i) to identify several promising biomarkers for severe forms of SARS-CoV-2 and also ii) to distinguish the molecular alterations induced by SARS-CoV-2 infection.

Consulter en ligne

Suggestions

Du même auteur

Value of a secretomic approach for distinguishing patients with COVID‐19 viral pneumonia among patients with respiratory distress admitted to intensive care unit

Archive ouverte | Blangy-Letheule, Angélique | CCSD

International audience. In intensive care units, COVID‐19 viral pneumonia patients (VPP) present symptoms similar to those of other patients with Nonviral infection (NV‐ICU). To better manage VPP, it is therefore in...

The secretome signature for identifying COVID-19 biomarkers severe forms

Archive ouverte | Blangy-Letheule, Angelique | CCSD

International audience

Secretome changes distinguishing severe forms of covid from critical pneumonia not related to SARS-COV-2 infection.

Archive ouverte | Blangy-Letheule, Angelique | CCSD

International audience

Chargement des enrichissements...